Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 67.2%

Neg 67.2% Neu 0% Pos 0%

Stifel analyst Laura Prendergast maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $15.